Paloma Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Paloma Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-8,200	Closed	-$1.2M	–	2092
2017 Q3	$1.2M	Buy	+8,200	New	+$1.24M	0.02%	1066

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Paloma Partners's JAZZ Position: Q3 2025 in Review

Paloma Partners sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2025, closing a stake of 3,481 shares — an estimated $369K sold.

Paloma Partners first reported a position in JAZZ in Q2 2013 and held it in 17 quarters. The position peaked at $16.4M in Q2 2016. 502 funds tracked by Wall St. Rank hold JAZZ as of Q3 2025.

Paloma Partners reported no remaining Jazz Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Paloma Partners sold 3,481 Jazz Pharmaceuticals shares in Q3 2025, an estimated $369K.
Paloma Partners first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 17 quarters.
Paloma Partners's Jazz Pharmaceuticals position peaked at $16.4M in Q2 2016.
502 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2025.

Based on Paloma Partners's 13F filing for Q3 2025, filed 14 Nov 2025.